Merck KGaA to develop Domain's adenosine receptor antagonists in immuno-oncology

23 January 2017

German pharma major Merck KGaA (NYSE: MRK) has entered into a licensing and collaboration agreement to develop Domain Therapeutics’ adenosine receptor programs for use in combination with immune checkpoint inhibitors.

The deal for worldwide rights will be worth more than 240 million euros ($258) in milestones to Domain, a French and Canadian privately-held company which is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting to discover and find therapeutics for central nervous system (CNS) diseases and cancer.

This deal focuses on the latter therapy area, explained Pascal Neuville, chief executive of Domain.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK